Axonics (AXNX) Set to Announce Quarterly Earnings on Monday

Axonics (NASDAQ:AXNX - Get Free Report) is set to release its earnings data on Monday, April 29th.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.07. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. The business had revenue of $109.70 million for the quarter, compared to analyst estimates of $107.33 million. During the same quarter in the prior year, the firm earned $0.01 EPS. The firm's quarterly revenue was up 27.7% compared to the same quarter last year. On average, analysts expect Axonics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axonics Stock Performance

Axonics stock traded up $0.15 during trading hours on Friday, reaching $66.69. 318,433 shares of the company's stock traded hands, compared to its average volume of 921,149. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -512.96 and a beta of 0.56. The firm's 50 day moving average is $67.90 and its 200-day moving average is $62.79. Axonics has a fifty-two week low of $47.59 and a fifty-two week high of $69.68.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. CL King reissued a "neutral" rating on shares of Axonics in a research note on Friday, January 12th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $71.00 price target (up previously from $68.00) on shares of Axonics in a research note on Wednesday, January 10th. Truist Financial reaffirmed a "hold" rating and issued a $71.00 price target (down previously from $73.00) on shares of Axonics in a research note on Friday, January 12th. Wolfe Research cut Axonics from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, January 9th. Finally, SVB Leerink reiterated a "market perform" rating and issued a $71.00 target price on shares of Axonics in a research report on Friday, January 12th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Axonics has a consensus rating of "Hold" and a consensus target price of $70.73.

Insider Buying and Selling

In other Axonics news, EVP John Woock sold 15,899 shares of the business's stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $1,076,998.26. Following the sale, the executive vice president now directly owns 77,403 shares of the company's stock, valued at $5,243,279.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP John Woock sold 15,899 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $1,076,998.26. Following the completion of the sale, the executive vice president now owns 77,403 shares in the company, valued at $5,243,279.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kari Leigh Keese sold 3,489 shares of the firm's stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $236,344.86. Following the completion of the sale, the chief financial officer now directly owns 43,323 shares of the company's stock, valued at $2,934,700.02. The disclosure for this sale can be found here. Insiders have sold a total of 65,837 shares of company stock worth $4,459,798 in the last ninety days. 1.85% of the stock is owned by insiders.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.